Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP
dc.contributor.author | Bodur, Hatice | |
dc.contributor.author | Ataman, Şebnem | |
dc.contributor.author | Buğdaycı, Derya Soy | |
dc.contributor.author | Rezvani, Aylin | |
dc.contributor.author | Nas, Kemal | |
dc.contributor.author | Uzunca, Kaan | |
dc.contributor.author | Emlakçıoğlu, Emel | |
dc.contributor.author | Karatepe, Altınay Göksel | |
dc.contributor.author | Durmuş, Bekir | |
dc.contributor.author | Sezgin, Melek | |
dc.contributor.author | Ayhan, Figen | |
dc.contributor.author | Yazgan, Pelin | |
dc.contributor.author | Duruöz, Tuncay | |
dc.contributor.author | Yener, Mahmut | |
dc.contributor.author | Gürğan, Alev | |
dc.contributor.author | Kırnap, Mehmet | |
dc.contributor.author | Çakar, Engin | |
dc.contributor.author | Soydemir, Raikan | |
dc.contributor.author | Çapkın, Erhan | |
dc.contributor.author | Tekeoğlu, İbrahim | |
dc.contributor.author | Aydın, Gülümser | |
dc.contributor.author | Günendi, Zafer | |
dc.contributor.author | Nacır, Barış | |
dc.contributor.author | Şallı, Ali | |
dc.contributor.author | Öztürk, Cihat | |
dc.contributor.author | Memiş, Asuman | |
dc.contributor.author | Turan, Yasemin | |
dc.contributor.author | Kozanoğlu, Erkan | |
dc.contributor.author | Sivrioğlu, Konçuy | |
dc.contributor.buuauthor | Altan, Lale | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi. | tr_TR |
dc.contributor.researcherid | AAH-1652-2021 | tr_TR |
dc.contributor.scopusid | 6603281363 | tr_TR |
dc.date.accessioned | 2022-02-28T09:25:30Z | |
dc.date.available | 2022-02-28T09:25:30Z | |
dc.date.issued | 2012-01 | |
dc.description.abstract | A web-based application patient follow-up program was developed to create a registry of patients with ankylosing spondylitis (AS) by the Turkiye Romatizma Arastirma Savas Dernegi (TRASD) AS Study Group. This study describes the methodological background and patient characteristics. The patient follow-up program is a web-based questionnaire, which contains sections on socio-demographic data, anamnesis, personal and family history, systemic and musculoskeletal examination, laboratory and imaging data and treatment. Between October 1, 2007 and February 28, 2009, 1,381 patients from 41 centers were included in the registry (1,038 males [75.2%]; mean age 39.5 +/- A 10.7 years). Mean disease duration was 12.1 +/- A 8.5 years, and mean time from initial symptom to diagnosis was 5 +/- A 6.8 years (median 2 years). HLA-B27 positivity was detected in 73.7% of 262 patients tested. Manifestations of extraarticular involvement were anterior uveitis (13.2%), psoriasis and other skin and mucous membrane lesions (6%) and inflammatory bowel disease (3.8%). The prevalence of peripheral arthritis was 11.2%. In 51.7% of patients, the Bath AS Disease Activity Index was a parts per thousand yen4. But since our patients consisted of the ones with more severe disease who referred to the tertiary centers and needed a regular follow-up, they may not represent the general AS population. Disease-modifying anti-rheumatic drugs were being used by 41.9% of patients, with 16.4% using anti-TNF agents. TRASD-IP (Izlem Programi: Follow-up program) is the first AS registry in Turkey. Such databases are very useful and provide a basis for data collection from large numbers of subjects. TRASD-IP gives information on the clinical and demographic profiles of patients, and the efficacy and safety of anti-TNF drugs, examines the impact on quality of life, and provides real-life data that may be used in cost-effectiveness analyses. | en_US |
dc.description.sponsorship | Wyeth/Pfizer Company | en_US |
dc.identifier.citation | Bodur, H. vd. (2012). "Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP". Rheumatology International, 32(1), 169-176. | en_US |
dc.identifier.endpage | 176 | tr_TR |
dc.identifier.issn | 0172-8172 | |
dc.identifier.issn | 1437-160X | |
dc.identifier.issue | 1 | tr_TR |
dc.identifier.pubmed | 20711591 | tr_TR |
dc.identifier.scopus | 2-s2.0-84857115884 | tr_TR |
dc.identifier.startpage | 169 | tr_TR |
dc.identifier.uri | https://doi.org/10.1007/s00296-010-1599-7 | |
dc.identifier.uri | https://link.springer.com/article/10.1007/s00296-010-1599-7 | |
dc.identifier.uri | http://hdl.handle.net/11452/24727 | |
dc.identifier.volume | 32 | tr_TR |
dc.identifier.wos | 000299007300027 | tr_TR |
dc.indexed.pubmed | Pubmed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer Heidelberg | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Rheumatology International | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Rheumatology | en_US |
dc.subject | Ankylosing spondylitis | en_US |
dc.subject | Patient registry | en_US |
dc.subject | Quality-of-life | en_US |
dc.subject | Rheumatoid-arthritis | en_US |
dc.subject | Reliability | en_US |
dc.subject | Validity | en_US |
dc.subject.emtree | Disease modifying antirheumatic drug | en_US |
dc.subject.emtree | Hla b27 antigen | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Anamnesis | en_US |
dc.subject.emtree | Ankylosing spondylitis | en_US |
dc.subject.emtree | Arthritis | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cost effectiveness analysis | en_US |
dc.subject.emtree | Disease course | en_US |
dc.subject.emtree | Disease duration | en_US |
dc.subject.emtree | Disease registry | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Drug safety | en_US |
dc.subject.emtree | Enteritis | en_US |
dc.subject.emtree | Family history | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Follow up | en_US |
dc.subject.emtree | Health survey | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Internet | en_US |
dc.subject.emtree | Iridocyclitis | en_US |
dc.subject.emtree | Laboratory test | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Medical examination | en_US |
dc.subject.emtree | Prevalence | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Psoriasis | en_US |
dc.subject.emtree | Quality of life | en_US |
dc.subject.emtree | Turkey (republic) | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Antirheumatic agents | en_US |
dc.subject.mesh | Arthritis | en_US |
dc.subject.mesh | Comorbidity | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Follow-up studies | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Internet | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Prevalence | en_US |
dc.subject.mesh | Quality of life | en_US |
dc.subject.mesh | Questionnaires | en_US |
dc.subject.mesh | Registries | en_US |
dc.subject.mesh | Retrospective studies | en_US |
dc.subject.mesh | Severity of illness index | en_US |
dc.subject.mesh | Spondylitis, ankylosing | en_US |
dc.subject.mesh | Treatment outcome | en_US |
dc.subject.mesh | Tumor necrosis factor-alpha | en_US |
dc.subject.mesh | Turkey | en_US |
dc.subject.scopus | Ankylosing Spondylitis; Sacroiliac Joint; Spondylarthropathies | en_US |
dc.subject.wos | Rheumatology | en_US |
dc.title | Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP | en_US |
dc.type | Article | |
dc.wos.quartile | Q3 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: